The effect of Farnesoid X receptor agonist tropifexor on liver damage in rats with experimental obstructive jaundice

ABSTRACT

Purpose:

To investigate experimentally the effects of Tropifexor, a farnesoid X receptor agonist, on liver injury in rats with obstructive jaundice.

Methods:

Forty healthy Wistar albino female rats were divided randomly in selected groups. These groups were the sham group, control group, vehicle solution group, Ursodeoxycholic acid group and Tropifexor group. Experimental obstructive jaundice was created in all groups, except the sham one. In the blood samples obtained, aspartate transaminase (AST), alanine transaminase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transferase (GGT), total bilirubin and direct bilirubin levels were established and recorded. Additionally, liver malondialdehyde, myeloperoxidase and catalase enzyme activity in the tissue samples were studied. Histopathological analysis was also performed.

Results:

No statistical difference was found between the control group and the Tropifexor group when AST, ALT and ALP values were compared. However, it was found that the Tropifexor group had statistically significant decreases in the values of GGT, total bilirubin and direct bilirubin (p < 0.05). Additionally, Tropifexor decreased the median values of malondialdehyde and myeloperoxidase, but this difference was not statistically significant compared to the control group. Finally, the Tropifexor group was statistically significant in recurring histopathological liver damage indicators (p < 0.05).

Conclusions:

Tropifexor reduced liver damage due to obstructive jaundice.

Key words
Cholestasis; Liver; Jaundice; Ursodeoxycholic acid; Rats

Introduction

Obstructive jaundice (OJ) is the clinical condition of bile retention and jaundice which occurs due to partial or complete obstruction of intrahepatic or extrahepatic bile ducts. While choledocholithiasis and biliary structures are the leading benign causes in OJ etiology, pancreatic cancer, cholangiocarcinoma, and ampullary tumors are the leading malignant causes¹,². Bile flow into the intestine is blocked in these kinds of diseases, due to the obstruction in the bile ducts, interrupting the enterohepatic cycle. In this way, bile accumulates in the liver cells and bile ducts. As a result, increased serum levels of bile acids and bilirubin can cause liver damage. This can also cause other conditions such as cardiovascular problems, kidney failure, delay in wound healing, gastrointestinal bleeding, bacterial translocation, sepsis, multi-organ dysfunction, and death¹,³.

Despite OJ being a significant health problem due to its high morbidity and mortality rates, there is no drug in routine clinical usage to prevent organ damage caused by the condition. The leading cause of liver damage in OJ is cellular damage due to bile stasis. The conventional treatment in OJ is to treat the causes of the obstruction directly. Conversely, liver damage can be prevented indirectly by reducing bile acid synthesis from the liver, thereby preventing bile retention.

The Farnesoid X receptor (FXR) is a nuclear receptor that acts as the primary regulator in the synthesis, conjugation, and transport of bile, and is highly expressed in the liver, gallbladder, intestines, and kidneys. Studies have shown that FXR agonists increase liver regeneration and have antioxidant, anti-inflammatory and hepatoprotective functions⁴. Some recent developed FXR agonist pharmacological agents have been reported to have promising results in reducing liver damage in treating non-alcoholic steatohepatitis (NASH) and primary biliary cholangitis (PBC) diseases⁴,⁵. Many other new FXR agonist pharmacological agents are currently being studied. One of them is Tropifexor (TPX), which is a potent and effective FXR agonist⁵.

The primary purpose of this study was to investigate experimentally the effects of TPX on liver injury in rats with OJ. Its effectiveness was compared with Ursodeoxycholic acid (UDCA), which is clinically used to treat cholestatic diseases and has no FXR agonist feature.

Methods

This study was carried out at Kahramanmaras Sütçü Imam University (KSU), Medical Faculty, Experimental Research Laboratory, with the permission of the KSU Animal Experiments Local Ethics Committee (KSUTIP HADYEK), decision dated 1st Aug 2019, Session No. 2,018/07 and Decision No. 08. Also, the European Convention for the Protection of Vertebrates Used for Experimental and Other Scientific Purposes (ETS No. 123), reported by the Council of Europe, was followed in this study. Biochemical evaluations were made in the Department of Medical Biochemistry, and histopathological evaluations were performed in the Pathology Department, both being departments in the KSU Medical Faculty.

Selection of animals and experimental conditions

In this experimental study, 40 healthy Wistar albino female rats were used. The rats were 12-14 weeks old, weighed the average of 250 ± 20 g, and each cage was populated with four rats. The animals were monitored at the average room temperature of 22 ± 2°C with suitable humidity, 12 hours of daylight and 12 hours of darkness. Standard industrial rat food was used in their diet. In the 12 hours before surgery, the rats were prevented from feeding, but they were allowed to drink water.

Experimental groups

Five groups were created, with eight randomly selected rats in each:

• Group 1: sham (SH) was designed to compare the possible effects of anesthetic agents and the surgical process with other groups to standardize the study;

• Group 2: control (C) was designed to demonstrate the biochemical and histopathological changes caused by OJ and compare the effectiveness of the treatment groups;

• Group 3: vehicle solution (VS) was designed to differentiate the possible effects of the vehicle solution used in the oral intake of TPX, containing 0.5% methylcellulose in distilled water and 0.5% Tween 80;

• Group 4: TPX was the FXR agonist group, designed to show the effects of TPX on biochemical and histopathological parameters;

• Group 5: UDCA was designed to compare the FXR agonist’s effectiveness to UDCA since the latter cannot activate FXR when used in the treatment of cholestatic diseases.

Anesthesia and surgical procedures

Anesthesia was employed before all surgical procedures and administered with 50 mg/kg Ketamine hydrochloride (HCL) (Ketas, Parke-Davis, Istanbul, Turkey) and 25 mg/kg Xylazine HCL (Rompun, Bayer, Istanbul, Turkey). After the anesthetic took effect, the abdomen hair of each animal was shaved. Rats were placed on the treatment table in a supine position and thoroughly disinfected by staining with 10% povidone-iodine (Poviodeks, 1,000 mL, Kimpa, Istanbul, Turkey), excluding the extremities and the upper part of the neck. Preparation for surgery was completed by covering the abdominal midline with sterile dressings.

In the SH group, the rats were subjected to laparotomy, and then the main bile duct was exposed, and the abdomen closed without additional surgery. In the other four groups, rats underwent a standard laparotomy, in which the main bile duct was isolated. The main bile duct was tied with 4/0 silk sutures, double in proximal and single in distal. Then, to prevent recanalization, the main bile duct was cut, thus creating OJ.

After the surgical procedures were completed, approximately 5 mL of saline was administered to all rats for fluid resuscitation. All groups were closed with continuous sutures in three layers using silk stitches. Feeding with standard rat food was continued for 6 hours post-operatively.

Follow-up and drug application

After the procedure, rats were observed for clinical signs of OJ such as yellowness in the ears and mucosal surfaces, and also examined for any darkening in urine color. OJ was observable as of the third day in the groups in which the main bile duct ligation was applied.

For postoperative analgesia, 28.5 mg/kg of tramadol was used subcutaneously every 12 for 48 hours. No treatment was given to neither the SH group nor to the C group in the postoperative period. Standard food and water quantities were given to these groups for 10 days.

In the VS group, only standard food and water were given in the first three days post-operatively. After that, the carrier solution was prepared with 0.5% methylcellulose and 0.5% Tween 80 in distilled water and was given for seven days from the fourth day post-operatively with the help of an orogastric tube. Food and water intake were not restricted.

In the TPX group, only standard food and water were given in the first three days post-operatively. From the fourth day, a dose of 0.01 mg/kg/day of TPX was given in a carrier solution, administered for seven days with the assistance of an orogastric tube. The dosage of 0.01 mg/kg/dayof TPX employed in the current study is based on Tully et al.⁵. Food and water intake were not restricted.

In the UDCA group, only standard food and water were given in the first three days after surgery. The treatment of UDCA acid (Ursofalk^®, Aris, Istanbul, Turkey), prepared at 25 mg/kg/day, was given with an orogastric tube for seven days from the fourth day post-operatively. Food and water intake were not restricted.

Tissue and blood samples

On the tenth postoperative day, Ketamine 50 mg/kg/i.p.and 25 mg/kg Xylazine HCL were given to the animals per the standard laboratory conditions. Anesthesia was administered, and the abdomen was reopened from the midline. Blood was collected intra-cardiac by thoracotomy and placed into gel tubes. The livers of the animals were removed entirely and divided into two parts. For standardization, the right liver lobes were taken for histopathological examination and placed in separate containers with 10% buffered formaldehyde added. The left liver lobes were also stored under the same conditions.

Biochemical analyses

The serum was separated by applying 5 minutes of centrifuge at 6,500 rpm to the blood samples. In the serum obtained, aspartate transaminase (AST U/L), alanine transaminase (ALT U/L), alkaline phosphatase (ALP U/L), gamma-glutamyl transferase (GGT U/L), total bilirubin (Tbil) (mg/dL) and direct bilirubin (Dbil) (mg/dL) levels were determined by Chemwell Biochemistry and the Energy Information Administration (EIA) auto-analysis device by photometric, enzymatic, and kinetic methods. As soon as the liver tissue was removed, it was placed on ice and dried with blotter paper. Before proceeding with homogenizing the tissues, 1.15% KCI was added to the tissues to provide dissolution. Tissues were homogenized at a speed of 16,000 rpm for 3 minutes. To prevent enzyme activation loss, samples were placed in an ice-filled bath. The homogenates were then centrifuged at +4°C at 14,000 rpm for 30 minutes. In the prepared homogenates, malondialdehyde (MDA), myeloperoxidase (MPO) and catalase enzyme levels in the tissue were measured as oxidant indicators and antioxidant parameters.

Histopathological examination

For histopathological examination, tissue from the right liver lobe was fixed with a 10% buffered formalin solution. After routine tissue follow-up, 3.5 µm serial sections were taken and stained with hematoxylin-eosin (H&E). A histopathologist performed blind evaluations of the liver damage indicators with a Nikon Eclipse Ni microscope.

The following histopathological observed changes were evaluated and scored:

• 1: Sinusoidal congestion/vacuolization;

• 2: Parenchymal cell necrosis;

• 3: Bile duct proliferation.

The changes were graded by giving scores from 0 to 4 for each group. The score descriptions were as follows:

• Score 0: No change;

• Score 1: Very Light;

• Score 2: Mild;

• Score 3: Medium;

• Score 4: Severe⁶.

Statistical analysis

The package program used for data statistical analysis was Statistical Package for the Social Sciences (SPSS) 23.0. The data were expressed as the means ± standard deviation (SD). Pearson’s chi-squared analysis was used to compare variables. The tendency of variables to a normal distribution was examined using the Shapiro-Wilk test. If the data did not show normal distribution, the Kruskal-Wallis test was used to evaluate the difference between the groups. If there were a statistically significant difference between the groups, they were compared with each other using the Conover test. The statistical significance level was taken as 0.05 in all tests and stated as such when p < 0.05.

Results

Liver function tests

Since no OJ was formed in the SH group, AST, ALT, ALP, GGT and bilirubin values were lower than in the other groups. The median ALP value in the TPX group was 335 IU/L (min-max: 212-2,205 IU/L), while the median in the C group was 893.86 IU/L (min-max: 265-1,548 IU/L). In the TPX group, ALP values were lower than in the C group, but the difference was not statistically significant. Considering the case with the ALP values, when the TPX group and the C group were compared in terms of ALT and AST, there were no statistically significant differences.

While the GGT median value was 18.36 IU/L (min-max: 11-31 IU/L) in the TPX group, the result was 46 IU/L (min-max: 27-80 IU/L) in the C group. This value was 40.07 IU/L (min-max: 14-53 IU/L) in the VS group. The GGT value was lower in the TPX group than in the C and VS groups, and this difference was significant (p < 0.001 and p < 0.001, respectively). When the median Tbil and Dbil values were examined according to the groups, the TPX group was 6.45 (min-max: 5.17-9 mg/dL) and 6.03 mg/dL (min-max: 4.97-8.4 mg/dL), respectively. In the UDCA group, the result for Tbil was 8.86 mg/dL (min-max: 6.47-9.32 mg/dL) and for Dbil it was 8.16 mg/dL (min-max: 4.94-8.77 mg/dL). In group C, the Tbil result was 8.48 mg/dL (min-max: 7.58-10 mg/dL), and the Dbil result was 8.04 mg/dL (min-max: 7.42-9.44 mg/dL). It was observed that the bilirubin values were lower by a statistically significant amount in the TPX group compared to the UDCA and C groups (p < 0.002, p < 0.002 / p < 0.009, p < 0.001, respectively). Liver function results for all groups are shown in Table 1.

Table 1
Median values (min-max) of liver function tests and comparison of TPX with other groups.

	AST (U/L)	ALT (U/L)	ALP (IU/L)	GGT (IU/L)	TBil (mg/dL)	DBil (mg/dL)
SH median (min-max)	109.5 (90-160) *	45 (37-62) *	253.5 (166-1,610)	0 (0-1) *	0.04 (0.01-0.06) *	0.02 (0.01-0.05) *
VS median (min-max)	401 (258-1,768)	102.5 (54-337)	494 (257-1,413)	40.07 (14-53) *	8.81 (3.78- 10.36) *	8.39 (3.46-9.89) *
C median (min-max)	354.36 (189-551)	81.5 (57-116)	893.86 (265-1,548)	46 (27-80) *	8.48 (7.58-10) *	8.04 (7.42-9.44) *
UDCA median (min-max)	524.15 (243.4-797.2)	79.41 (44.6-103.1)	269.64 (180-423)	21 (19-50)	8.86 (6.47-9.32) *	8.16 (4.94-8.77) *
TPX median (min-max)	452.57 (191-833)	78.71 (50-107)	335 (212-2,205)	18.36 (11-31)	6.45 (5.17-9)	6.03 (4.97-8.4)

• SH: sham group; VS: vehicle solution group; C: control group; UDCA: Ursodeoxycholic acid group; TPX: Tropifexor group; AST: aspartate transaminase; ALT: alanine transaminase; ALP: alkaline phosphatase; GGT: gamma-glutamyl transferase; Tbil: total bilirubin; Dbil: direct bilirubin;
• ^*
  statistically significant different TPX vs. other groups (p < 0.05).

Liver tissue oxidant-antioxidant parameters

In the TPX group, the median tissue MDA values were 1.47 nmol/mg (min-max: 0.64-2.66 nmol/mg), and the median tissue MPO values were 90.03 U/g (min-max: 75.93-107 U/g). In group C, the MDA median values were 1.9 nmol/mg (min-max: 0.92-3.03 nmol/mg), and the MPO median values were 97.25 U/g (min-max: 72.22-111.11 U/g). Although these oxidant parameters were lower in the TPX group than in the C group, the observed decrease was not statistically significant (Table 2). There was no statistically significant difference between the tissue catalase value of the TPX group and the other groups.

Table 2
Liver tissue oxidant-antioxidant median (min-max) parameters and comparison of TPX with other groups.

	Catalase (U/mg protein)	MDA (nml/mg protein)	MPO (U/g protein
SH median (min-max)	231.47 (54.59-315.79)	2.66 (0.85-3.27) *	98.39 (86.8-113.02)
VS median (min-max)	120.62 (46.61-285.38)	2.65 (0.64-4.03)	108.31 (92.35-160.5) *
C median (min-max)	88.97 (50.86-159.84)	1.9 (0.92-3.03)	97.25 (72.22-111.11)
UDCA median (min-max)	119.38 (41.91-166)	2.56 (1.72-3.76) *	87.09 (69.25-107.34)
TPX median (min-max)	98.87 (75.24-130.83)	1.47 (0.64-2.66)	90.03 (75.93-107)

• SH: sham group; VS: vehicle solution group; C: control group; UDCA: Ursodeoxycholic acid group; TPX: Tropifexor group; MDA: malondialdehyde, MPO: myeloperoxidase;
• ^*
  statistically significant different TPX vs. other groups (p < 0.05).

Histopathology

It was observed that there were normal liver findings in the SH group (Fig. 1). Sinusoidal congestion/vacuolization, necrosis in the parenchymal cells, and bile duct proliferation were all moderately more severe compared to the C and VS groups. The difference in the severity was statistically significant (Figs. 2 and 3). However, there was no statistically significant difference between the TPX and UDCA groups according to the distribution of histopathological findings (p > 0.05) (Table 3).

Table 3
Histopathological changes and comparison of TPX with other groups.

Score (0-4)	Sinusoidal congestion / vacuolization	Parenchymal cell necrosis	Bile duct proliferation	(n)
TPX	2, 1, 2, 1, 1, 1, 2, 2	2, 1, 1, 1, 2, 1, 1, 2	1, 2, 2, 1, 1, 1, 2, 2	8
SH	0, 0, 0, 1, 0, 1, 1, 0	0, 0, 0, 0, 0, 0, 0, 1	0, 1, 1, 1, 0, 0, 1, 0	8
VS	4, 3, 2, 3, 2, 3, 4, 2 *	3, 4, 2, 3, 3, 2, 3, 4 *	4, 3, 3, 4, 2, 3, 4, 2 *	8
C	2, 3, 2, 3, 4, 3, 2, 3 *	2, 4, 4, 3, 2, 3, 3, 3 *	2, 3, 3, 4, 2, 4, 3, 3 *	8
UDCA	2, 2, 2, 1, 1, 1, 1, 1	2, 1, 1, 2, 1, 1, 1, 2	1, 1, 1, 2, 2, 1, 2, 2	8

• SH: sham group; VS: vehicle solution group; C: control group; UDCA: Ursodeoxycholic acid group; TPX: Tropifexor group;
• ^*
  statistically significant different TPX vs. other groups (p < 0.05).

Figure 1
Normal histopathological view from the sham group (hematoxylin-eosin x200).

Figure 2
Severe areas of necrosis in the liver from the control group (hematoxylin-eosin x200)

Figure 3
Moderate signs of sinusoid congestion/vacuolization and necrosis in parenchymal cells from the Tropifexor group (hematoxylin-eosin x200).

Discussion

Two main factors come to the fore in the physiopathology of liver injury occurring in OJ. The first one is the hepatotoxic effects caused by bile salts and bilirubin due to bile stasis. The other factor is the deterioration in the balance of oxidative and antioxidant systems in the liver and increased lipid peroxidation⁷. This damage can be prevented with a drug that can reduce bile acid synthesis and exhibit antioxidant properties, targeting the elimination of these OJ related causes of liver damage.

In the biochemical findings of patients with OJ, AST, ALT, ALP, GGT and bilirubin values increase due to the toxic effect of cholestasis⁸. There are elevated biochemical AST, ALT, ALP and GGT values in NASH disease, which is associated with a fatty liver, inflammation, hepatocyte swelling, and fibrosis. The same occurs in PBC disease, an autoimmune cholestatic disease. The level of liver enzymes is a significant predictor in evaluating the effectiveness of the treatments given in NASH and PBC diseases. UDCA is the first and most preferred drug used in treating PBC patients, effectively reducing liver enzymes and inhibiting liver damage.

However, some PBC patients do not respond to treatment with UDCA, and in those cases the disease continues to show progression. Recently, studies have been carried out with various FXR agonists to treat these patient groups which do not respond to treatments⁹. FXR is an NR and decreases bile acid synthesis and absorption while increasing excretion. Thus, it plays a key role in bile acid metabolism. Moreover, FXR activation has been shown to increase liver regeneration and to have anti-inflammatory and antioxidant effects¹⁰,¹¹.

In a double-blind, placebo-controlled phase-3 study performed by Nevens et al.¹², it was observed that serum ALP and Tbil levels decreased. This was especially the case with PBC patients who did not respond to UDCA and who were in the group receiving obeticholic acid (OCA), an FXR agonist. The researchers also reported that OCA was effective in healing the disease by decreasing AST, ALT, and GGT serum levels. In the NASH murine model study, Zhang et al.¹³ showed that WAY-362450, an FXR agonist, decreased AST function and ALT values. According to the published preliminary results of the phase-2 placebo-controlled study with Cilofexor (an FXR agonist) in PBC patients, AST, ALT, GGT and ALP serum levels were effectively reduced¹⁴.

In the biochemical results of the current study, no statistically significant difference was found in the serum levels of AST, ALT and ALP between the TPX group and the other ones. According to the authors’ view, this is due to the 7-day TPX treatment duration in this study. Eloy et al.¹⁰, in their study with the NASH animal model, stated decreased AST and ALT values after the second week of TPX treatment. Therefore, it is hypothesized that, if the TPX treatment period were extended, similar results would be achieved in this study.

The serum levels of GGT, Tbil, and Dbil levels in this study’s TPX group were lower by a statistically significant amount compared to those of the control group. Nevens et al.¹² and Liu et al.¹⁵ also showed that FXR agonists effectively lows ALP level. Additionally, Liu et al.¹⁵ reported that FXR agonist GW4064 decreased bilirubin values, but this was not statistically significant compared to taurodeoxycholic acid. However, in the current study the TPX group’s bilirubin values were statistically and significantly lower than both the UDCA and control groups. This improvement in cholestasis parameters is due to TPX (an FXR agonist) reducing bile synthesis and the accompanying anti-inflammatory activity. The achievement of lower serum levels of GGT, Tbil, and Dbil due to TPX is an important indicator for its future application in OJ.

Increased intraductal pressure caused by bile retention in OJ and cellular swelling in hepatocytes creates an ischemic injury. Subsequently, an increase in the production of superoxide radicals (SOR) occurs, and excessive SOR formation leads to polymorphonuclear leukocyte (PMNL) activation. In these cases, mediators released by PMNL in the form of a cycle increase SOR production even more. Accordingly, oxidative stress and an increase in lipid peroxidation induced by SOR cause damage to the liver and biliary tract⁷,¹⁶. Under normal conditions, SOR is rendered ineffective after its removal by antioxidant mechanisms. However, increasing SOR and decreasing antioxidant activity in OJ, the balance between oxidative and antioxidative systems deteriorates. As a result, antioxidants remain inadequate and facilitate the occurrence of liver damage⁷.

Tsuji et al.¹⁷ reported that PMNL activation and cytokine and SOR production from neutrophils increased more in OJ rats than in normal rats. Alturfan et al.¹⁸ also reported that MPO and MDA levels, which are indicators of PMNL activation, increased in rats with OJ, which was consistent with liver damage. Livero et al.¹⁹ gave mice 6-alfa-ethil-chenodeoxycholic acid (ECDCA) (obeticholic acid:OCA), which is an FXR agonist, after generating hepatic steatosis with ethanol in them. They showed that, in the group given 6-ECDCA, catalase and SOD activity increased, and oxidative stress decreased. Eloy et al.¹⁰ in a study in which they investigated the antioxidant activity of TPX reported that it up-regulates glutathione S-transferase a4 and glutathione S-transferase genes, which are dose-dependent antioxidant genes.

The current study evaluated liver tissue MDA and MPO levels as oxidative markers and liver tissue catalase levels as antioxidant markers. It was observed that the mean tissue MDA value of the TPX group was lower than in all the other groups. However, this result was not statistically significant when compared to the control group. The efficiency of TPX was not detected in other oxidative markers studied. It is possible this observation was related to the dose and duration of TPX used in this study. Tully et al.⁵, in their paper regarding the discovery of TPX, showed that, as the dose of TPX increased, its effectiveness increased. Therefore, the current authors’ view is that, increasing the TPX dose and duration of treatment, better outcomes would be achieved on oxidative and antioxidative parameters.

Liu et al.¹⁵ showed that bile duct proliferation, parenchymal necrosis and inflammatory cell infiltration were increased in OJ rats and that these findings regressed significantly in the group given the FXR agonist GW4064. Hu et al.²⁰ reported that, histopathologically, the vacuolization and inflammation findings were significantly reduced in the group given INT-767 (an FXR agonist).

In the present study, the measurement of sinusoidal congestion/vacuolization, presence of necrosis in parenchymal cells and bile duct proliferation were evaluated as histopathological markers of liver damage. It was found that the difference between the TPX group and the C and VS groups were found to be statistically significant in the improvement of histopathologic liver damage markers. This is an indication of TPX’s potential effectiveness in preventing liver damage in OJ. However, no statistically significant difference was found between the TPX group and the UDCA group. This may show that TPX and UDCA have a similar level of effect after all. UDCA is a commercial drug with clinical use. The fact that TPX appears as effective as UDCA demonstrates that this issue is worth investigating. Consistent with the literature on the topic, it must be emphasized that TPX is a promising agent and that, as an FXR agonist, it is effective in reducing liver damage histopathologically in rats with OJ.

As with all studies, this one comes with some limitations. Some weaknesses include the low sample size and the application of TPX in a narrow dose range. The short duration of treatment of TPX can also be considered a limitation. Alternatively, if evaluated together with the literature on reducing liver damage due to OJ, it can be said that TPX is a potentially effective agent. However, additional studies are needed in this regard before clinical usage begins.

Conclusion

This study showed that TPX is effective in reducing liver damage in rats with OJ. TPX may be a viable step forward in the treatment of OJ, reducing morbidity and mortality, although additional experimental and clinical studies are needed.

Acknowledgments

Not applicable.

• Data availability statement

  Data will be available upon request.

• Funding

  Not applicable.
• Research performed at Experimental Research Laboratory, Medical Faculty, Kahramanmaraş

References

• ¹
  Wang L, Yu WF. Obstructive jaundice and perioperative management. Acta Anaesthesiol Taiwan. 2014;52(1):22-9. https://doi.org/10.1016/j.aat.2014.03.002
  » https://doi.org/10.1016/j.aat.2014.03.002
• ²
  Turk O, Badak B, Ateş E, Dundar E, Sutken E. The role of growth factors on hepatic damage in rats with obstructive jaundice, Springerplus. 2016;5(1):1274. https://doi.org/10.1186/s40064-016-2919-5
  » https://doi.org/10.1186/s40064-016-2919-5
• ³
  Su CH, Peng FK, Lui WY. Factors affecting morbidity and mortality in biliary tract surgery. World J Surg. 1992; 16(3):536-40. https://doi.org/10.1007/BF02104465
  » https://doi.org/10.1007/BF02104465
• ⁴
  Chiang JYL. Bile acids: regulation of synthesis J. Lipid Res. 2009;50:1955-66. https://doi.org/10.1194/jlr.R900010-JLR200
  » https://doi.org/10.1194/jlr.R900010-JLR200
• ⁵
  Tully DC, Rucker PV, Chianelli D, Williams J, Vidal A, Alper PB, Mutnick D, Bursulaya B, Schmeits J, Wu X, Bao D, Zoll J, Kim Y, Groessl T, McNamara P, Seidel HM, Molteni V, Liu B, Phimister A, Joseph SB, Laffitte B. Discovery of tropifexor (LJN452), a highly potent nonbile acid FXR agonist for the treatment of cholestatic liver diseases and nonalcoholic steatohepatitis (NASH). J Med Chem. 2017;60(24):9960-73. https://doi.org/10.1021/acs.jmedchem.7b00907
  » https://doi.org/10.1021/acs.jmedchem.7b00907
• ⁶
  Suzuki S, Toledo-Pereyra LH, Rodriguez FJ, Cejalvo D. Neutrophil infiltration as an important factor in liver ischemia and reperfusion injury. Modulating effects of FK506 and cyclosporine. Transplantation. 1993;55:1265-72. https://doi.org/10.1097/00007890-199306000-00011
  » https://doi.org/10.1097/00007890-199306000-00011
• ⁷
  Montilla P, Cruz A, Padillo FJ, Tunez I, Gascon F, Munoz MJ, Gomez M, Pera C. Melatonin versus vitamin E as a protective treatment against oxidative stress after extrahepatic bile duct ligation in rats. J Pineal Res. 2001;31:138-44. https://doi.org/10.1034/j.1600-079x.2001.310207.x
  » https://doi.org/10.1034/j.1600-079x.2001.310207.x
• ⁸
  Luo WW, Zhou XL, Wang QQ, Shao YJ, Li ZM, Zhao DK, Yu SP. The application of compont gel in chronic obstructive jaundice rats model. Acta Cir Bras. 2019;34(5):e201900504. https://doi.org/10.1590/s0102-865020190050000004
  » https://doi.org/10.1590/s0102-865020190050000004
• ⁹
  Beuers U, Trauner M, Jansen P, Poupon R. New paradigms in the treatment of hepatic cholestasis: from UDCA to FXR, PXR and beyond. J Hepatol. 2015;62(1):25-37. https://doi.org/10.1016/j.jhep.2015.02.023
  » https://doi.org/10.1016/j.jhep.2015.02.023
• ¹⁰
  Hernandez ED, Zheng L, Kim Y, Fang B, Liu B, Valdez RA, Dietrich WF, Rucker PV, Chianelli D, Schmeits J, Bao D, Zoll J, Dubois C, Federe GC, Chen L, Joseph SB, Klickstein LB, Walker J, Molteni V, McNamara P, Meeusen S, Tully DC, Badman MK, Xu J, Laffitte B. Tropifexor-mediated abrogation of steatohepatitis and fibrosis is associated with the antioxidative gene expression profile in rodents. Hepatol Commun. 2019;3(8):1085-97. https://doi.org/10.1002/hep4.1368
  » https://doi.org/10.1002/hep4.1368
• ¹¹
  Xie Y, Wang H, Cheng X, Wu Y, Cao L, Wu M, Xie W, Wang G, Hao H. Farnesoid X receptor activation promotes cell proliferation via PDK4-controlled metabolic reprogramming. Sci Rep. 2016;6:18751. https://doi.org/10.1038/srep18751
  » https://doi.org/10.1038/srep18751
• ¹²
  Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, Drenth JP, Pockros PJ, Regula J, Beuers U, Trauner M, Jones DE, Floreani A, Hohenester S, Luketic V, Shiffman M, van Erpecum KJ, Vargas V, Vincent C, Hirschfield GM, Shah H, Hansen B, Lindor KD, Marschall HU, Kowdley KV, Hooshmand-Rad R, Marmon T, Sheeron S, Pencek R, MacConell L, Pruzanski M, Shapiro D; POISE Study Group. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375(7):631-43. https://doi.org/10.1056/NEJMoa1509840
  » https://doi.org/10.1056/NEJMoa1509840
• ¹³
  Zhang S, Wang J, Liu Q, Harnish CH. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in a murine model of non-alcoholic steatohepatitis. J Hepatol. 2009;51:380-8. https://doi.org/10.1016/j.jhep.2009.03.025
  » https://doi.org/10.1016/j.jhep.2009.03.025
• ¹⁴
  Trauner M, Gulamhusein A, Hameed B, Caldwell S, Shiffman ML, Landis C, Eksteen B, Agarwal K, Muir A, Rushbrook S, Lu X, Xu J, Chuang JC, Billin AN, Li G, Chung C, Subramanian GM, Myers RP, Bowlus CL, Kowdley KV. The nonsteroidal FXR agonist cilofexor (GS-9674) improves markers of cholestasis and liver injury in patients with PSC. Hepatology. 2019;70(3):788-801. https://doi.org/10.1002/hep.30509
  » https://doi.org/10.1002/hep.30509
• ¹⁵
  Liu Y, Binz J, Numerick MJ, Dennis S, Luo G, Desai B, MacKenzie KI, Mansfield TA, Kliewer SA, Goodwin B, Jones SA. Hepatoprotection by the farnesoid X receptor agonist GW4064 in rat models of intra- and extrahepatic cholestasis. J Clin Invest. 2003;112(11):1678-87. https://doi.org/10.1172/JCI18945
  » https://doi.org/10.1172/JCI18945
• ¹⁶
  Ogetman Z, Dirlik M, Caglikulekci M, Canbaz H, Karabacak T, Yaylak F, Tamer L, Kanik A, Aydin S. The effect of aminoguanidine on blood and tissue lipid peroxidation in jaundiced rats with endotoxemia induced with LPS. J Invest Surg. 2006;19(1):19-30. https://doi.org/10.1080/08941930500444396
  » https://doi.org/10.1080/08941930500444396
• ¹⁷
  Tsuji K, Kubota Y, Yamamoto S, Yanagitani K, Amoh Y, Takaoka M, Ogura M, Kin H, Inoue K. Increased neutrophil chemotaxis in obstructive jaundice: an in vitro experiment in rats. J Gastroenterol Hepatol. 1999;14(5):457-63. https://doi.org/10.1046/j.1440-1746.1999.01880.x
  » https://doi.org/10.1046/j.1440-1746.1999.01880.x
• ¹⁸
  Alturfan AA, Aytaç E, Emekli-Alturfan E, Yarat A, Sarıbeyoğlu K, Pekmezci S, Seymen O. Serum total sialic acid as a novel complementary candidate marker of hepatic damage in obstructive jaundice. Ann Clin Lab Sci. 2014;44(1):56-61. https://doi.org/0091-7370/14/0100-056
  » https://doi.org/0091-7370/14/0100-056
• ¹⁹
  Lívero FA, Stolf AM, Dreifuss AA, Bastos-Pereira AL, Chicorski R, de Oliveira LG, de Souza CE, Fabossi IA, Rabitto IS, Gremski LH, Henneberg R, Telles JE, Oude Elferink RP, Acco A. The FXR agonist 6ECDCA reduces hepatic steatosis and oxidative stress induced by ethanol and low-protein diet in mice. Chem Biol Interact. 2014;217:19-27. https://doi.org/10.1016/j.cbi.2014.03.014
  » https://doi.org/10.1016/j.cbi.2014.03.014
• ²⁰
  Hu YB, Liu XY, Zhan W. Farnesoid X receptor agonist INT-767 attenuates liver steatosis and inflammation in a rat model of non-alcoholic steatohepatitis. Drug Des Devel Ther. 2018;12:2213-21. https://doi.org/10.2147/DDDT.S170518
  » https://doi.org/10.2147/DDDT.S170518

Publication Dates

• Publication in this collection
  25 Oct 2021
• Date of issue
  2021

History

• Received
  02 May 2021
• Reviewed
  03 July 2021
• Accepted
  05 Aug 2021